COUNTERFEIT MEDICINES

IN LEGITIMATE SUPPLY CHAINS*

A study by
University of California, San Diego School of Medicine & the Pharmaceutical Security Institute (PSI)

Download here the study *Counterfeit Drug Penetration into Global Legitimate Medicine Supply Chains: A Global Health Assessment*

Download here the full infographic *Counterfeit medicines in legitimate supply chains*

* Mackey TK, Liang BA, York P, Kubic T. Counterfeit Drug Penetration into Global Legitimate Supply Chains: A Global Assessment. Am J. Trop. Med. Hyg; 2015; doi:10.4269/ajtmh.14-0389 [advanced online publication]

IFPMA

Pharmaceutical Security Institute



of all counterfeit medicines detected in the legitimate supply chain are

lifesaving-related treatments:

21.1%	11.6%	11.0%	9.1%
Anti-infective*	**Cardiovascular**	**Central nervous system**	**Alimentary**

*including both branded and generic anti-infectives/antibiotics, such as anti-malarial

ROUTE OF ADMINISTRATION:

77.3%	15.4%
were oral dosage formulations	were injectable biologicals

COUNTERFEIT MEDICINES

IN LEGITIMATE SUPPLY CHAINS*

A study by
University of California, San Diego School of Medicine & the Pharmaceutical Security Institute (PSI)

Download here the study *Counterfeit Drug Penetration into Global Legitimate Medicine Supply Chains: A Global Health Assessment*

Download here the full infographic *Counterfeit medicines in legitimate supply chains*

* Mackey TK, Liang BA, York P, Kubic T. Counterfeit Drug Penetration into Global Legitimate Supply Chains: A Global Assessment. Am J. Trop. Med. Hyg; 2015; doi:10.4269/ajtmh.14-0389 [advanced online publication]

IFPMA

Pharmaceutical Security Institute

REPORTS ON COUNTERFEIT MEDICINES ARE LACKING. BASED ON PSI REPORTING SYSTEM ANALYSIS FOUND THAT:

35.2%
more than one-third of the nations in the world had their legitimate supply chain compromised

51.3%
of the reports contained limited information precluding further classification

SOURCES OF REPORT SHOW A GREAT DIFFERENCE BETWEEN REGIONS:

Middle income markets were most represented



- 42.0% Asia
- 24.6% America
- 17.4% Africa
- 14.5% Europe
- 1.4% Oceania



- 7.2% Ukraine
- 8.4% Russia
- 10.9% Uzbekistan
- 11.6% Peru

5 countries represent 65.7% of all reports :

- 27.6% China

COUNTERFEIT MEDICINES IN LEGITIMATE SUPPLY CHAINS*

A study by
University of California, San Diego School of Medicine & the Pharmaceutical Security Institute (PSI)

Download here the study *Counterfeit Drug Penetration into Global Legitimate Medicine Supply Chains: A Global Health Assessment*

Download here the full infographic *Counterfeit medicines in legitimate supply chains*

* Mackey TK, Liang BA, York P, Kubic T. Counterfeit Drug Penetration into Global Legitimate Supply Chains: A Global Assessment. Am J. Trop. Med. Hyg; 2015; doi:10.4269/ajtmh.14-0389 [advanced online publication]

IFPMA

Pharmaceutical Security Institute

Improvements in surveillance, including detection of security breaches, data collection, analysis, and dissemination are urgently needed to address the public health need to combat the global counterfeit medicines trade

CONCLUSIONS:

Three key needs emerged from this study:

- greater consistency, standardization and robust data collection for analysis,
- enhanced reporting by countries,
- increased details in the reports.

RECOMMENDATIONS:

- development and coordination of a "single point of contact" system comprised of relevant country authorities to conduct surveillance and reporting counterfeit incidents to a central global system,
- development of a "graded best practices" set of guidelines supporting ongoing training, capacity building, technical assistance, data sharing, and partnership. These guidelines should be developed in cooperation with regulatory authorities, law enforcement, customs, pharmaceutical companies, academic institutions, and other stakeholders.